VRTX Vertex Pharmaceuticals Incorporated

Price (delayed)

$207.46

Market cap

$54.04B

P/E Ratio

25.87

Dividend/share

N/A

EPS

$8.02

Enterprise value

$49.73B

Sector: Healthcare
Industry: Biotechnology
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Highlights

The gross profit has soared by 58% YoY and by 13% from the previous quarter
VRTX's revenue has soared by 56% YoY and by 12% QoQ
Vertex Pharmaceuticals's net income has increased by 38% QoQ but it has decreased by 6% YoY
The EPS has increased by 37% since the previous quarter but it has declined by 8% year-on-year

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
260.47M
Market cap
$54.04B
Enterprise value
$49.73B
Valuations
Price to earnings (P/E)
25.87
Price to book (P/B)
7.15
Price to sales (P/S)
9.97
EV/EBIT
21.75
EV/EBITDA
20.79
EV/Sales
9.2
Earnings
Revenue
$5.4B
EBIT
$2.29B
EBITDA
$2.39B
Free cash flow
$2.56B
Per share
EPS
$8.02
Free cash flow per share
$9.85
Book value per share
$29
Revenue per share
$20.81
TBVPS
$33.95
Balance sheet
Total assets
$10.22B
Total liabilities
$2.7B
Debt
$522.07M
Equity
$7.52B
Working capital
$4.9B
Liquidity
Debt to equity
0.07
Current ratio
3.72
Quick ratio
3.47
Net debt/EBITDA
-1.8
Margins
EBITDA margin
44.3%
Gross margin
87.7%
Net margin
38.5%
Operating margin
38.9%
Efficiency
Return on assets
23.8%
Return on equity
32.9%
Return on invested capital
79.6%
Return on capital employed
27.2%
Return on sales
42.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$5.4B
Gross profit
$4.74B
Operating income
$2.1B
Net income
$2.08B
Gross margin
87.7%
Net margin
38.5%
The operating income has surged by 139% year-on-year and by 28% since the previous quarter
The gross profit has soared by 58% YoY and by 13% from the previous quarter
VRTX's revenue has soared by 56% YoY and by 12% QoQ
The operating margin has soared by 53% YoY and by 14% QoQ

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
P/E
25.87
P/B
7.15
P/S
9.97
EV/EBIT
21.75
EV/EBITDA
20.79
EV/Sales
9.2
The EPS has increased by 37% since the previous quarter but it has declined by 8% year-on-year
The price to earnings (P/E) is 29% less than the last 4 quarters average of 36.2
The stock's price to book (P/B) is 56% less than its 5-year quarterly average of 16.1 and 23% less than its last 4 quarters average of 9.3
The equity has grown by 48% YoY and by 16% from the previous quarter
VRTX's revenue has soared by 56% YoY and by 12% QoQ
The price to sales (P/S) is 34% less than the 5-year quarterly average of 15.1 and 24% less than the last 4 quarters average of 13.1

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on invested capital has surged by 137% year-on-year and by 32% since the previous quarter
The return on sales has surged by 61% year-on-year and by 14% since the previous quarter
The return on equity has declined by 36% year-on-year but it has grown by 25% since the previous quarter
VRTX's return on assets is down by 34% year-on-year but it is up by 25% since the previous quarter

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets has increased by 45% YoY and by 15% QoQ
The total liabilities has increased by 37% YoY and by 11% QoQ
VRTX's debt is 93% lower than its equity
The equity has grown by 48% YoY and by 16% from the previous quarter
The debt to equity fell by 42% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.